Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN4A | P35499 | 1/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.32 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.31 |
| ▸ | UCHL1 | P09936 | 2/20 | 0.31 |
| ▸ | STS | P08842 | 1/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31569557 | 0.88 | SCN4A (0.35) | SCN4ASCN5ASCN3AGRAMD1AADORA1 | |
| SCHEMBL31569400 | 0.87 | SCN4A (0.36) | SCN4ASCN5ASCN3AMEN1KMT2A | |
| SCHEMBL31568968 | 0.86 | SCN4A (0.36) | SCN4ASCN5ASCN3AMEN1KMT2A | |
| SCHEMBL22647477 | 0.86 | SCN4A (0.49) | SCN4ASCN5ASCN3AMEN1KMT2A | |
| SCHEMBL24061284 | 0.86 | SCN4A (0.49) | SCN4ASCN5ASCN3AMEN1KMT2A | |
| SCHEMBL31568970 | 0.85 | SCN4A (0.35) | SCN4ASCN5ASCN3AMEN1KMT2A | |
| SCHEMBL31569524 | 0.85 | MEN1 (0.37) | SCN4ASCN5ASCN3AMEN1KMT2A | |
| SCHEMBL31569443 | 0.84 | GRAMD1A (0.39) | SCN4ASCN5ASCN3AMEN1KMT2A | |
| SCHEMBL31569513 | 0.84 | SCN4A (0.37) | SCN4ASCN5ASCN3AMEN1KMT2A | |
| SCHEMBL31569174 | 0.84 | SCN4A (0.35) | SCN4ASCN5ASCN3AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT INC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2025101780-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | OCTANT, INC. (US) | 2025-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115174-A1 | PHARMACOLOGICAL CORRECTORS OF RHODOPSIN AND USES THEREOF | PDE6D, PDE6H, ADRA1D | SCN4A 36/4885SCN5A 186/4885SCN3A 80/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.